IN8bio, Inc.

NASDAQ: INAB · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001740279Reports USD

#1 of 1,402 Healthcare companies by revenue

EA Score

——

FH 52DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$19.4M

Employees

Market cap

$14.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$19.4M-$19.4M2025

Operating income-$19.4M-$19.4M2025

Total assets$32.3M$32.3M2025

Liabilities$4.7M$4.7M2025

Equity$27.6M$27.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

IN8bio, Inc. earned -$19.4M in FY2025 net income.

Peers · Healthcare

Finch Therapeutics Group, Inc.——SeaStar Medical Holding Corporation31D Moleculin Biotech, Inc.37D Lipocine Inc.49D

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B60C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B56C

Key facts

CEOTai-Wei

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: INAB

Employees18

IPO date2021-07-30

Latest filings

8-K2026-06-01 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-03-26 10-K2026-03-12 8-K2026-03-12 8-K2026-02-27 8-K2026-02-09

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.